Kadmon Corp. LLC, of New York, said it established a Cooperative Research and Development Agreement with the National Institute of Dental and Craniofacial Research (NIDCR) to develop an adeno-associated virus vector containing human aquaporin-1 gene (AAV2hAQP1) for the treatment of xerostemia resulting from the use of ionizing radiation (IR) in the treatment of head and neck cancer.